Next 10 |
home / stock / lobef / lobef news
12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformat...
L-130 passes 12 months ongoing stability Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a propriet...
Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Officer,...
Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase agreeme...
Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an Inte...
First-in-Man trial for Lobe’s proprietary stabilized psilocin analogue All subjects dosed with no significant adverse events to date Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative m...
2023-06-07 07:29:39 ET Biopharmaceutical company Lobe Sciences ( OTCQB:LOBEF ) said on Wednesday that Baxter Phillips III has been appointed to the newly created position of COO, effective immediately. The position was created to provide additional executive leadership. Additi...
Phillips also named President of Altemia & Co., a Lobe Sciences Company Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxte...
2023-05-17 09:15:50 ET Lobe Sciences ( OTCQB:LOBEF ) has entered into a commercial distribution agreement with Pentec Health, Inc. for the supply and distribution of Altemia. Altemia is Lobe's proprietary formulation of emulsified docosahexaenoic acid ethyl ester (DHA) concentrati...
News, Short Squeeze, Breakout and More Instantly...
Lobe Sciences Ltd Company Name:
LOBEF Stock Symbol:
OTCMKTS Market:
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.&nbs...
12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"...
Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformat...